Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

273
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
273
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Divergent PET Tracer Avidity in Synchronous Sarcomatoid Carcinoma With Osteosarcomatous Differentiation and Adenocarcinoma of the Prostate: Insights From Dual-Tracer 68Ga-PSMA and 18F-FDG PET/CT Imaging.

Clinical nuclear medicine·2026
Same author

FDG PET/CT as the Decisive Modality in Distinguishing Clear Cell Sarcoma from Melanoma When Immunohistochemistry Overlaps: A Case Report.

World journal of nuclear medicine·2026
Same author

PSMA PET/CT imaging for biochemical recurrence in prostate cancer: can it replace conventional imaging and guide salvage therapy?

Annals of nuclear medicine·2026
Same author

Baseline fluorodeoxyglucose PET/computed tomography volumetric parameters predict response to transarterial radioembolization in primary and metastatic liver tumors.

Nuclear medicine communications·2026
Same author

Perfusion-only Q-SPECT as a rule-out tool for CTEPH in resource-limited settings: a feasibility study on reducing unnecessary referrals to tertiary centers.

BMC pulmonary medicine·2026
Same author

Beyond discovery: are we understanding PET tracers as fast as we invent them? a critical review.

EJNMMI research·2026

Related Experiment Video

Updated: Mar 7, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K

Metabolically Silent Diffuse Hepatic Involvement in Multiple Myeloma: An 18F-FDG-PET/CT Pitfall.

Seçkin Bilgiç1, Merve Okuyan2, Efrah İbrahim1

  • 1Bursa Uludağ University Faculty of Medicine, Department of Nuclear Medicine, Bursa, Türkiye.

Molecular Imaging and Radionuclide Therapy
|March 6, 2026
PubMed
Summary

Diffuse hepatic involvement in multiple myeloma is rare. This case shows 18F-FDG PET/CT limitations in detecting it, highlighting the need for integrated diagnostics.

Keywords:
18F-FDG PET/CTdiagnostic pitfallhepatic myelomahepatomegalyliver biopsymultiple myeloma

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K

Related Experiment Videos

Last Updated: Mar 7, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K

Area of Science:

  • Oncology
  • Medical Imaging
  • Hematology

Background:

  • Diffuse hepatic involvement in multiple myeloma is an uncommon presentation.
  • It can pose diagnostic challenges, particularly with advanced imaging techniques.
  • Early and accurate diagnosis is crucial for effective management.

Purpose of the Study:

  • To report a rare case of diffuse hepatic involvement in multiple myeloma.
  • To illustrate the limitations of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in diagnosing this condition.
  • To emphasize the importance of multimodal diagnostic approaches.

Main Methods:

  • Case presentation of a 59-year-old male with a history of multiple myeloma.
  • Utilized 18F-FDG PET/CT to assess hepatic and skeletal involvement.
  • Performed liver biopsy for histopathological examination.
  • Monitored response to systemic therapy.

Main Results:

  • The patient presented with hepatomegaly and ascites.
  • 18F-FDG PET/CT showed diffuse liver enlargement but no significant hepatic 18F-FDG uptake, indicating a hypometabolic myeloma phenotype.
  • Liver biopsy confirmed diffuse sinusoidal infiltration by plasma cells, excluding amyloidosis.
  • Hepatomegaly and ascites resolved with treatment, yet hepatic 18F-FDG uptake remained absent.

Conclusions:

  • 18F-FDG PET/CT can be limited in detecting diffuse hepatic myeloma.
  • Discordance between morphological and metabolic findings necessitates further investigation.
  • Multimodal diagnostic strategies, including biopsy, are essential for accurate diagnosis and management of hepatic myeloma.